Paradigm reports results of patient study

Latest News

Paradigm Biopharmaceuticals (ASX:PAR) has announced that, in the 45 patients treated with the injectable Pentosan Polysulfate Sodium (PPS), 84.4 per cent responded with both a reduction in joint pain and an improvement in knee function.

Patients self-reported pain scores were reduced by an average of 50 per cent from baseline in the 45 patients with knee osteoarthritis (OA) and concurrent Bone Marrow Lesions (BML).

Patients were treated by their doctor with injectable PPS under the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS).

The company said the 50 per cent reduction in pain scores observed with PPS in knee OA demonstrates superiority over the 15 per cent pain reduction scores reported for opioid treatments.

"The comparative effects of PPS therapy against opioid treatments implies that the patient-reported data have provided evidence of clinically meaningful improvements in chronic pain," said the company

The results from 45 patient-reported outcomes comes in advance of data from the company's phase 2b randomised, double-blind, placebo-controlled, multicentre, clinical trial, which is expected in later this year. 

“We are very pleased to see the second group of Real World Evidence patients report results that are consistent with the first group of patients we treated under the program," said Paradigm CEO Paul Rennie.